Table 2.
Comparison of laboratory variables with the results of renal scintigraphy in the study group.
| Variables | Severe Scars | Moderate Scars | Borderline Lesions |
|---|---|---|---|
| (1) | (2) | (3) | |
| No. patients (%) | 32 (39.5%) | 31 (38.3%) | 18 (22.2%) |
| Laboratory data | |||
| Serum Cr (mg/dL) | 0.35 (0.3; 0.5) | 0.3 (0.3; 0.5) | 0.5 (0.33; 0.6) |
| Cystatin C (mg/L) | 0.90 ± 0.22 | 0.91 ± 0.23 | 0.92 ± 0.21 |
| GFR (mL/min/1.73 m2) | 107.47 ± 21.37 | 106.70 ± 15.5 | 106.18 ± 19.11 |
| ACR (mg/g) | 17.22 (7.31; 25.00) | 19.2 (9.06; 26.74) | 9.45 (4.09; 24.28) |
| Urinary biomarkers | |||
| TGF-β1 (ng/mL) | 0.039 ± 0.018 | 0.036 ± 0.020 | 0.040 ± 0.026 |
| Endoglin (ng/mL) | 9.07 ± 4.57 | 9.22 ± 3.25 | 7.70 ± 2.31 |
| Periostin (ng/mL) | 0.098 (0.073; 0.208) | 0.080 (0.063; 0.125) | 0.102 (0.034; 0.149) |
| Cytokeratin-18 (ng/mL) | 0.370 ± 0.142 | 0.391 ± 0.153 | 0.394 ± 0.174 |
| TGF-β1/Cr (ng/mg) | 0.095 (0.034; 0.286) | 0.088 (0.026; 0.238) | 0.038 (0.014; 0.228) |
| Endoglin/Cr (ng/mg) | 22.16 (8.30; 60.55) | 25.16 (8.65; 62.36) | 9.73 (4.48; 44.45) |
| Periostin/Cr (ng/mg) | 0.342 (0.161; 0.616) * | 0.269 (0.172; 0.473) | 0.110 (0.070; 0.250) |
| Cytokeratin-18/Cr (ng/mg) | 0.976 (0.355; 2.188) | 0.961 (0.530; 1.774) | 0.442 (0.268; 1.530) |
Cr—creatinine; GFR—estimated glomerular filtration rate; ACR—urinary albumin/creatinine ratio; TGF-β1—transforming growth factor-β1. * p—0.010 versus borderline lesions.